Log In
Print
BCIQ
Print
Print this Print this
 

MLN1117 (formerly INK1117)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionInhibitor of Phosphoinositide 3-kinase (PI3K) alpha
Molecular Target Phosphoinositide 3-kinase (PI3K) alpha
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) alpha inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid malignancies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$239.0M

$119.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today